Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 92

1.

Risk loci for chronic obstructive pulmonary disease: a genome-wide association study and meta-analysis.

Cho MH, McDonald ML, Zhou X, Mattheisen M, Castaldi PJ, Hersh CP, Demeo DL, Sylvia JS, Ziniti J, Laird NM, Lange C, Litonjua AA, Sparrow D, Casaburi R, Barr RG, Regan EA, Make BJ, Hokanson JE, Lutz S, Dudenkov TM, Farzadegan H, Hetmanski JB, Tal-Singer R, Lomas DA, Bakke P, Gulsvik A, Crapo JD, Silverman EK, Beaty TH; NETT Genetics, ICGN, ECLIPSE and COPDGene Investigators.

Lancet Respir Med. 2014 Mar;2(3):214-25. doi: 10.1016/S2213-2600(14)70002-5. Epub 2014 Feb 7.

2.

Infant siblings and the investigation of autism risk factors.

Newschaffer CJ, Croen LA, Fallin MD, Hertz-Picciotto I, Nguyen DV, Lee NL, Berry CA, Farzadegan H, Hess HN, Landa RJ, Levy SE, Massolo ML, Meyerer SC, Mohammed SM, Oliver MC, Ozonoff S, Pandey J, Schroeder A, Shedd-Wise KM.

J Neurodev Disord. 2012 Apr 18;4(1):7. doi: 10.1186/1866-1955-4-7.

3.

The Study to Explore Early Development (SEED): a multisite epidemiologic study of autism by the Centers for Autism and Developmental Disabilities Research and Epidemiology (CADDRE) network.

Schendel DE, Diguiseppi C, Croen LA, Fallin MD, Reed PL, Schieve LA, Wiggins LD, Daniels J, Grether J, Levy SE, Miller L, Newschaffer C, Pinto-Martin J, Robinson C, Windham GC, Alexander A, Aylsworth AS, Bernal P, Bonner JD, Blaskey L, Bradley C, Collins J, Ferretti CJ, Farzadegan H, Giarelli E, Harvey M, Hepburn S, Herr M, Kaparich K, Landa R, Lee LC, Levenseller B, Meyerer S, Rahbar MH, Ratchford A, Reynolds A, Rosenberg S, Rusyniak J, Shapira SK, Smith K, Souders M, Thompson PA, Young L, Yeargin-Allsopp M.

J Autism Dev Disord. 2012 Oct;42(10):2121-40.

4.

Prevalence, correlates, and viral dynamics of hepatitis delta among injection drug users.

Kucirka LM, Farzadegan H, Feld JJ, Mehta SH, Winters M, Glenn JS, Kirk GD, Segev DL, Nelson KE, Marks M, Heller T, Golub ET.

J Infect Dis. 2010 Sep 15;202(6):845-52. doi: 10.1086/655808.

5.

Progesterone and 17beta-estradiol enhance regulatory responses to human papillomavirus type 16 virus-like particles in peripheral blood mononuclear cells from healthy women.

Marks MA, Gravitt PE, Burk RD, Studentsov Y, Farzadegan H, Klein SL.

Clin Vaccine Immunol. 2010 Apr;17(4):609-17. doi: 10.1128/CVI.00441-09. Epub 2010 Feb 3.

6.

Sexual activity and Kaposi's sarcoma among human immunodeficiency virus type 1 and human herpesvirus type 8-coinfected men.

Nawar EW, Cole SR, Farzadegan H, Witt MD, Jenkins FJ, Margolick JB, Phair JP, Jacobson LP.

Ann Epidemiol. 2008 Jul;18(7):517-21. doi: 10.1016/j.annepidem.2008.03.009. Epub 2008 May 27.

7.

Multiperson use of syringes among injection drug users in a needle exchange program: a gene-based molecular epidemiologic analysis.

Shrestha S, Smith MW, Broman KW, Farzadegan H, Vlahov D, Strathdee SA.

J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):335-43.

PMID:
16980914
8.

Localization of human herpesvirus type 8 in human sperms by in situ PCR.

Bagasra O, Patel D, Bobroski L, Abbasi JA, Bagasra AU, Baidouri H, Harris T, El-Roeiy A, Lengvarszky Z, Farzadegan H, Wood C.

J Mol Histol. 2005 Sep;36(6-7):401-12. Epub 2006 Jan 10.

PMID:
16402152
9.

Sexual risk behavior among injection drug users before widespread availability of highly active antiretroviral therapy.

Rusch ML, Farzadegan H, Tarwater PM, Safaeian M, Vlahov D, Strathdee SA.

AIDS Behav. 2005 Sep;9(3):289-99.

PMID:
16133905
10.

The effect of RANTES chemokine genetic variants on early HIV-1 plasma RNA among African American injection drug users.

Duggal P, Winkler CA, An P, Yu XF, Farzadegan H, O'Brien SJ, Beaty TH, Vlahov D.

J Acquir Immune Defic Syndr. 2005 Apr 15;38(5):584-9.

PMID:
15793370
11.

Evaluation of possible effects of continued drug use on HIV progression among women.

Rompalo AM, Shah N, Margolick JB, Farzadegan H, Arnsten J, Schuman P, Rich JD, Gardner LI, Smith DK, Vlahov D; HIV Epidemiology Research Study Group.

Int J STD AIDS. 2004 May;15(5):322-7.

PMID:
15117502
12.

High-risk behavior and potential transmission of drug-resistant HIV among injection drug users.

Sethi AK, Celentano DD, Gange SJ, Gallant JE, Vlahov D, Farzadegan H.

J Acquir Immune Defic Syndr. 2004 Apr 15;35(5):503-10.

PMID:
15021315
13.

Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans.

Duggal P, An P, Beaty TH, Strathdee SA, Farzadegan H, Markham RB, Johnson L, O'Brien SJ, Vlahov D, Winkler CA.

Genes Immun. 2003 Jun;4(4):245-50.

PMID:
12761559
14.

Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users.

Arnsten JH, Demas PA, Grant RW, Gourevitch MN, Farzadegan H, Howard AA, Schoenbaum EE.

J Gen Intern Med. 2002 May;17(5):377-81.

15.

Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring.

Arnsten JH, Demas PA, Farzadegan H, Grant RW, Gourevitch MN, Chang CJ, Buono D, Eckholdt H, Howard AA, Schoenbaum EE.

Clin Infect Dis. 2001 Oct 15;33(8):1417-23. Epub 2001 Sep 5.

16.

Tampons as a self-administered collection method for the detection and quantification of genital HIV-1.

Webber MP, Schoenbaum EE, Farzadegan H, Klein RS.

AIDS. 2001 Jul 27;15(11):1417-20.

PMID:
11504963
17.

Short tandem repeat methodology for genotypic identification of single-person versus multi-person use of syringes.

Shrestha S, Strathdee SA, Brahmbhatt H, Farzadegan H, Vlahov D, Smith MW.

AIDS. 2000 Jul 28;14(11):1507-13.

PMID:
10983637
18.

Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection.

Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, Farzadegan H, Gupta P, Rinaldo CR, Learn GH, He X, Huang XL, Mullins JI.

J Virol. 1999 Dec;73(12):10489-502.

19.

The effect of drug-injection behavior on genetic evolution of HIV-1.

Carneiro M, Yu XF, Lyles C, Templeton A, Weisstein AE, Safaeian M, Farzadegan H, Vlahov D, Markham RB.

J Infect Dis. 1999 Oct;180(4):1025-32.

PMID:
10479127
20.

Comparison of clinical manifestations of HIV infection among women by risk group, CD4+ cell count, and HIV-1 plasma viral load. HER Study Group. HIV Epidemiology Research.

Rompalo AM, Astemborski J, Schoenbaum E, Schuman P, Carpenter C, Holmberg SD, Warren DL, Farzadegan H, Vlahov D, Smith DK.

J Acquir Immune Defic Syndr Hum Retrovirol. 1999 Apr 15;20(5):448-54.

PMID:
10225226
21.

Cell-associated infectious HIV-1 viral load as a predictor of clinical progression and survival among HIV-1 infected injection drug users and homosexual men.

Lyles CM, Graham NM, Astemborski J, Vlahov D, Margolick JB, Saah AJ, Farzadegan H.

Eur J Epidemiol. 1999 Feb;15(2):99-108.

PMID:
10204638
22.

Anti-HIV type 1 memory cytotoxic T lymphocyte responses associated with changes in CD4+ T cell numbers in progression of HIV type 1 infection.

Rinaldo CR Jr, Gupta P, Huang XL, Fan Z, Mullins JI, Gange S, Farzadegan H, Shankarappa R, Muñoz A, Margolick JB.

AIDS Res Hum Retroviruses. 1998 Nov 1;14(16):1423-33.

PMID:
9824320
23.

Sex differences in HIV-1 viral load and progression to AIDS.

Farzadegan H, Hoover DR, Astemborski J, Lyles CM, Margolick JB, Markham RB, Quinn TC, Vlahov D.

Lancet. 1998 Nov 7;352(9139):1510-4.

PMID:
9820299
24.

Comparison of two measures of human immunodeficiency virus (HIV) type 1 load in HIV risk groups.

Lyles CM, Vlahov D, Farzadegan H, Astemborski J, Margolick JB, Masters BA, Schroeder J, Quinn TC.

J Clin Microbiol. 1998 Dec;36(12):3647-52.

25.

Patterns of HIV-1 evolution in individuals with differing rates of CD4 T cell decline.

Markham RB, Wang WC, Weisstein AE, Wang Z, Munoz A, Templeton A, Margolick J, Vlahov D, Quinn T, Farzadegan H, Yu XF.

Proc Natl Acad Sci U S A. 1998 Oct 13;95(21):12568-73.

26.
27.

Sustained cognitive decline in HIV infection: relationship to CD4+ cell count, plasma viremia and p24 antigenemia.

Dal Pan GJ, Farzadegan H, Selnes O, Hoover DR, Miller EN, Skolasky RL, Nance-Sproson TE, McArthur JC.

J Neurovirol. 1998 Feb;4(1):95-9.

PMID:
9531016
28.

Vitamin A supplementation and human immunodeficiency virus load in injection drug users.

Semba RD, Lyles CM, Margolick JB, Caiaffa WT, Farzadegan H, Cohn S, Vlahov D.

J Infect Dis. 1998 Mar;177(3):611-6.

PMID:
9498439
29.

Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count.

Vlahov D, Graham N, Hoover D, Flynn C, Bartlett JG, Margolick JB, Lyles CM, Nelson KE, Smith D, Holmberg S, Farzadegan H.

JAMA. 1998 Jan 7;279(1):35-40.

PMID:
9424041
30.

Diagnosis of human immunodeficiency virus infection using citrated whole blood.

Sharma UK, Song HF, Willingham FF, Hannig J, Flexner C, Farzadegan H, Nicolau C, Schwartz DH.

Clin Diagn Lab Immunol. 1997 May;4(3):261-3.

31.

Vitamin A levels and human immunodeficiency virus load in injection drug users.

Semba RD, Farzadegan H, Vlahov D.

Clin Diagn Lab Immunol. 1997 Jan;4(1):93-5.

32.

Virologic and serologic markers of rapid progression to AIDS after HIV-1 seroconversion.

Farzadegan H, Henrard DR, Kleeberger CA, Schrager L, Kirby AJ, Saah AJ, Rinaldo CR Jr, O'Gorman M, Detels R, Taylor E, Phair JP, Margolick JB.

J Acquir Immune Defic Syndr Hum Retrovirol. 1996 Dec 15;13(5):448-55.

PMID:
8970472
33.

The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study.

Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ.

J Infect Dis. 1996 Dec;174(6):1332-6.

PMID:
8940228
34.

Detection of Kaposi's sarcoma herpesvirus DNA in semen of homosexual men with Kaposi's sarcoma.

Gupta P, Singh MK, Rinaldo C, Ding M, Farzadegan H, Saah A, Hoover D, Moore P, Kingsley L.

AIDS. 1996 Nov;10(13):1596-8. No abstract available.

PMID:
8931799
35.

HIV-1 survival kinetics in peritoneal dialysis effluent.

Farzadegan H, Ford D, Malan M, Masters B, Scheel PJ Jr.

Kidney Int. 1996 Nov;50(5):1659-62.

36.

Selective transmission of human immunodeficiency virus type 1 variants to SCID mice reconstituted with human peripheral blood monoclonal cells.

Markham RB, Schwartz DH, Templeton A, Margolick JB, Farzadegan H, Vlahov D, Yu XF.

J Virol. 1996 Oct;70(10):6947-54.

37.

Racial differences in rate of CD4 decline in HIV-1-infected homosexual men.

Easterbrook PJ, Farzadegan H, Hoover DR, Palenicek J, Chmiel JS, Kaslow RA, Saah AJ.

AIDS. 1996 Sep;10(10):1147-55.

PMID:
8874633
38.

Evaluation of an infectivity standard for real-time quality control of human immunodeficiency virus type 1 quantitative micrococulture assays. Participating Laboratories of The AIDS Clinical Trials Group.

Scott WA, Brambilla D, Siwak E, Beatty C, Bremer J, Coombs RW, Farzadegan H, Fiscus SA, Hammer SM, Hollinger FB, Khan N, Rasheed S, Reichelderfer PS.

J Clin Microbiol. 1996 Sep;34(9):2312-5.

39.

Cohort study of cytomegalovirus infection as a risk factor for carotid intimal-medial thickening, a measure of subclinical atherosclerosis.

Nieto FJ, Adam E, Sorlie P, Farzadegan H, Melnick JL, Comstock GW, Szklo M.

Circulation. 1996 Sep 1;94(5):922-7.

PMID:
8790026
40.

The effect of latent Mycobacterium tuberculosis infection on human immunodeficiency virus (HIV) disease progression and HIV RNA load among injecting drug users.

Manoff SB, Farzadegan H, Muñoz A, Astemborski JA, Vlahov D, Rizzo RT, Solomon L, Graham NM.

J Infect Dis. 1996 Aug;174(2):299-308.

PMID:
8699059
41.

Mutual confounding and interactive effects between hepatitis C and hepatitis B viral infections in hepatocellular carcinogenesis: a population-based case-control study in Taiwan.

Sun CA, Farzadegan H, You SL, Lu SN, Wu MH, Wolfe L, Hardy W, Huang GT, Yang PM, Lee H, Chen CJ.

Cancer Epidemiol Biomarkers Prev. 1996 Mar;5(3):173-8.

42.
43.

Diagnostic utility of immune-complex-dissociated p24 antigen detection in perinatally acquired HIV-1 infection in Rwanda.

Bulterys M, Farzadegan H, Chao A, Dushimimana A, Voltz A, Nawrocki P, Kurawige JB, Saah AJ.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Oct 1;10(2):186-91.

PMID:
7552484
44.

Virologic and immunologic characterization of symptomatic and asymptomatic primary HIV-1 infection.

Henrard DR, Daar E, Farzadegan H, Clark SJ, Phillips J, Shaw GM, Busch MP.

J Acquir Immune Defic Syndr Hum Retrovirol. 1995 Jul 1;9(3):305-10.

PMID:
7788430
45.

Recovery of human immunodeficiency virus from peritoneal dialysis effluent.

Scheel PJ Jr, Farzadegan H, Ford D, Malan M, Watson A.

J Am Soc Nephrol. 1995 May;5(11):1926-9.

46.

Identification of human immunodeficiency virus primary isolates resistant to interferon-alpha and correlation of prevalence to disease progression.

Künzi MS, Farzadegan H, Margolick JB, Vlahov D, Pitha PM.

J Infect Dis. 1995 Apr;171(4):822-8.

PMID:
7706808
47.
48.

Occupational risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infections among funeral service practitioners in Maryland.

Gershon RR, Vlahov D, Farzadegan H, Alter MJ.

Infect Control Hosp Epidemiol. 1995 Apr;16(4):194-7.

PMID:
7636165
49.

Association between anti-CD4 antibodies and a decline in CD4+ lymphocytes in human immunodeficiency virus type 1 seroconverters.

Keay S, Wecksler W, Wasserman SS, Margolick J, Farzadegan H.

J Infect Dis. 1995 Feb;171(2):312-9.

PMID:
7844366
50.

Time course of detection of viral and serologic markers preceding human immunodeficiency virus type 1 seroconversion: implications for screening of blood and tissue donors.

Busch MP, Lee LL, Satten GA, Henrard DR, Farzadegan H, Nelson KE, Read S, Dodd RY, Petersen LR.

Transfusion. 1995 Feb;35(2):91-7.

PMID:
7825218

Supplemental Content

Loading ...
Support Center